Mira PHARMACEUTICALS, Inc. (MIRA) intrinsic value & 10-year financials
Mira PHARMACEUTICALS, Inc. (MIRA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.63
- Market cap
- $4.9M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 450.4%
- Free cash flow (FY2025)
- —
MIRA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$10.4M | -$1.35 | — | — | -165.9% |
| FY2024 | — | -$7.9M | -$0.51 | — | — | -238.9% |
| FY2023 | — | -$12.0M | -$0.64 | — | — | 1388.5% |
| FY2022 | — | -$7.1M | -$0.40 | — | — | 817.9% |
| FY2021 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
MIRA PHARMACEUTICALS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
MIRA PHARMACEUTICALS, INC. has historically struggled to out-earn its cost of capital, averaging just 4.5% ROIC.
MIRA PHARMACEUTICALS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
MIRA PHARMACEUTICALS, INC. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.